PRQR: רווח נקי למניה ב-12 החודשים האחרונים ProQR Therapeutics N.V.

Innovative RNA editing methods and patent protection shield ProQR Therapeutics N.V. (PRQR) from price wars. Analyzing the rolling net income per share metric on GURU.Markets, we see that the indicator value reaches -0.46. ProQR Therapeutics N.V. (PRQR) focuses on correcting mutations for orphan centers, establishing scientific alliances with global industry leaders to combat rare pathologies.

Net income per share over 12 months measures the final profitability of the business by distributing total income among all security holders to assess the real impact of operating expenses. Given the expenditures of ProQR Therapeutics N.V. (PRQR) to retain Axiomer platform experts and its partnership with Eli Lilly, the current trailing twelve-month net income per share reflects capital management efficiency and the resilience of fundamental value.